Keytruda and Polymyositis - a phase IV clinical study of FDA data

Summary:

Polymyositis is reported as a side effect among people who take Keytruda (pembrolizumab), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Jentadueto, and have Lung cancer - non-small cell.

The phase IV clinical study analyzes which people have Polymyositis when taking Keytruda. It is created by eHealthMe based on reports of 57,304 people who have side effects when taking Keytruda from the FDA, and is updated regularly.

What is Keytruda?

Keytruda has active ingredients of pembrolizumab. It is often used in renal cell carcinoma. eHealthMe is studying from 57,404 Keytruda users. Check the latest studies of Keytruda.

What is Polymyositis?

Polymyositis (inflammatory muscle disease that causes weakness of the skeletal muscles) is found to be associated with 249 drugs and 433 conditions by eHealthMe. Check the latest studies of Polymyositis.

On Jul, 29, 2026

57,304 people reported to have side effects when taking Keytruda.
Among them, 38 people (0.07%) have Polymyositis.

Among these 38 people:

How long have people been on Keytruda when they have Polymyositis? *

What is the gender of people who have Polymyositis when taking Keytruda? *

female: 28.57 %
male: 71.43 %

What is the age of people who have Polymyositis when taking Keytruda? *

What are other drugs people take besides Keytruda? *

What are other side effects people have besides Polymyositis? *

Hepatic Function Abnormal: 9 people, 23.68%
Weakness: 9 people, 23.68%
Eyelid Ptosis (falling of the upper or lower eyelid): 8 people, 21.05%
Myasthenia Gravis (a chronic condition that causes muscles to tire and weaken easily): 7 people, 18.42%
Malignant Neoplasm Progression (cancer tumour came back): 6 people, 15.79%
Hypercapnia (too much smoke): 4 people, 10.53%
Pneumonia: 4 people, 10.53%
Interstitial Lung Disease: 3 people, 7.89%
Pneumonia Aspiration (bronchopneumonia that develops due to the entrance of foreign materials into the bronchial tree): 3 people, 7.89%
Blood Creatine Phosphokinase Increased: 3 people, 7.89%

What are the existing conditions these people have? *

Lung Cancer - Non-Small Cell (lung cancer): 7 people, 18.42%
Lung Adenocarcinoma (a form of non-small cell lung cancer): 5 people, 13.16%
Malignant Melanoma (skin cancer rises from melancytes): 4 people, 10.53%
Metastatic Malignant Melanoma (spreadable cancer tumour of melanine): 3 people, 7.89%
Metastases To Lymph Nodes (cancer spreads to lymph node): 2 people, 5.26%
Cancer Pain: 2 people, 5.26%
Enlarged Prostate: 2 people, 5.26%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 2 people, 5.26%
High Blood Pressure: 2 people, 5.26%
Transitional Cell Carcinoma (cancer tumour inner most layer of urinary system): 2 people, 5.26%

* Approximation only. Some reports may have incomplete information.

Do you take Keytruda and have Polymyositis?

- Check whether Polymyositis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Keytruda:

Keytruda (57,404 reports)

Polymyositis treatments and more:

Polymyositis (5,024 reports)

Browse all side effects of Keytruda:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Polymyositis:

Polymyositis (249 drugs)

Browse all the conditions that are associated with Polymyositis:

Polymyositis (433 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on pembrolizumab (the active ingredients of Keytruda) and Keytruda (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.